Tseng Min-Hua, Lo Wen-Tsung, Lin Wei-Jen, Teng Ching-Shen, Chu Mong-Ling, Wang Chih-Chien
Department of Pediatrics, Tri-Service General Hospital, Taipei, Taiwan.
Pediatr Int. 2008 Dec;50(6):797-800. doi: 10.1111/j.1442-200X.2008.02738.x.
There is growing concern regarding antimicrobial resistance worldwide, particularly of Escherichia coli, and the first choice of an antimicrobial agent for empiric treatment of pediatric urinary tract infection (UTI) is not well established.
The medical records from January 1991 to December 2005 for all children under 18 years of age admitted to Tri-Service General Hospital, Taipei for their first UTI were reviewed. Two study periods, early (1991-2000) and late (2001-2005), were chosen during the 15 year period for evaluating the trend of antimicrobial resistance.
Of the 368 isolates, E. coli was the most common pathogen (81.0%), followed by Klebsiella pneumoniae (6.5%), Enterococcus spp. (6.0%), and Proteus mirabilis (3.5%). Of the 368 isolates, 77.4% were resistant to ampicillin, 44.6% to co-trimoxazole, 27.2% to cephalothin, 15.0% to gentamicin, and 8.4% to nitrofurantoin. In the early (1991-2000) and late (2001-2005) study periods, 199 isolates (54.1%) and 169 isolates (45.9%), respectively, were compared. The resistance to antimicrobial agents for overall pathogens in the early and late study periods, respectively, was as follows: 68.8% and 88.0% to ampicillin, 48.9% and 46.6% to co-trimoxazole, 26.8% and 28.9% to cephalothin, 16.2% and 19.8% to gentamicin, and 8.7% and 9.0% to nitrofurantoin.
Among commonly used antimicrobial agents for the treatment of pediatric UTI, there is a trend towards increasing resistance to ampicillin and a persistently low resistance rate to gentamicin, cephalosporin, and nitrofurantoin. Parenteral first-generation cephalosporins, gentamicin, and oral nitrofurantoin should be considered for first-line agents, given the resistance patterns of this study.
全球对抗菌素耐药性的关注日益增加,尤其是大肠杆菌,而用于儿童尿路感染(UTI)经验性治疗的抗菌药物的首选尚未明确。
回顾了1991年1月至2005年12月期间台北三军总医院收治的所有18岁以下首次患UTI儿童的病历。在这15年期间选择了两个研究阶段,早期(1991 - 2000年)和晚期(2001 - 2005年),以评估抗菌素耐药性的趋势。
在368株分离菌中,大肠杆菌是最常见的病原体(81.0%),其次是肺炎克雷伯菌(6.5%)、肠球菌属(6.0%)和奇异变形杆菌(3.5%)。在368株分离菌中,77.4%对氨苄西林耐药,44.6%对复方新诺明耐药,27.2%对头孢噻吩耐药,15.0%对庆大霉素耐药,8.4%对呋喃妥因耐药。在早期(1991 - 2000年)和晚期(2001 - 2005年)研究阶段,分别比较了199株(54.1%)和169株(45.9%)。早期和晚期研究阶段总体病原体对抗菌药物的耐药性分别如下:对氨苄西林为68.8%和88.0%,对复方新诺明为48.9%和46.6%,对头孢噻吩为26.8%和28.9%,对庆大霉素为16.2%和19.8%,对呋喃妥因分别为8.7%和9.0%。
在治疗儿童UTI常用的抗菌药物中,对氨苄西林的耐药性有增加趋势,而对庆大霉素、头孢菌素和呋喃妥因的耐药率持续较低。鉴于本研究的耐药模式,胃肠外第一代头孢菌素、庆大霉素和口服呋喃妥因应被视为一线药物。